Comparison
Piracetam vs Pramiracetam
Piracetam
The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. A cyclic derivative of GABA and the founding member of the racetam family.
Pramiracetam
Highly potent racetam (~15-30x piracetam by weight) targeting high-affinity choline uptake in the hippocampus.
| Field | Piracetam | Pramiracetam |
|---|---|---|
| Category | racetam | racetam |
| Dose range | 1200–4800mg | 300–600mg |
| Half-life | 5h | 5h |
| Onset | 45min | 30min |
| Evidence | EVIDENCEA | EVIDENCEB |
| Safety | ●●●●● | ●●●●○ |
| Legal (US) | USUnscheduled | USUnscheduled |
| PubMed refs | 1200 | 60 |
The comparison in plain English
Auto-generated from dataPiracetam and Pramiracetam are both in the racetam category respectively. Piracetam The original nootropic, developed in 1964 by Romanian chemist Corneliu Giurgea. Pramiracetam Highly potent racetam (~15-30x piracetam by weight) targeting high-affinity choline uptake in the hippocampus.
Bottom line
Piracetam (evidence A, safety 5/5) has a weaker evidence base than Pramiracetam (evidence B, safety 4/5). Piracetam has the slightly cleaner safety profile. For users new to either, the higher-evidence option is the safer first try.
Choose Piracetam if
Piracetam is the better fit when your goal aligns with its mechanism (Modulates AMPA and NMDA glutamate receptors and enhances acetylcholine signaling via muscarinic receptor allosteric modulation) and the dose range (1200–4800mg) suits your protocol. Half-life is 5h.
Choose Pramiracetam if
Pramiracetam is the better fit when your goal aligns with its mechanism (Highly selective enhancer of high-affinity choline uptake (HACU) in the hippocampus — the rate-limiting step in acetylcholine synthesis in cholinergic neurons) and the dose range (300–600mg) suits your protocol. Half-life is 5h.